Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Cedars Sinai has now started recruiting!

<< Previous

Bullboard Posts

Next >>

Comment by qwerty22on May 27, 2022 11:43am

127 Views

Post# 34712280

RE:RE:RE:Cedars Sinai has now started recruiting!

I was going on the resumption that the cancer type was probably just a box ticking process on a form and that they get the longer list of cancer types based on the 1a all-comer criteria.

SPCEO1 wrote: So, it appears that both Mary Crowley and Cedars Sinai are up and running now. Clinicaltrials.gov still do not acknowledge that but that is not surprising as the website is typically updated only sporadically. Now, we need to see some additional centers added to the list and we shoiu,d also see some European cancer test sites open but likely not until July as it takes longer to get going there.

I find it interesting how Crowley and Cedars Sinai describe the cancers they are looking at in the TH-1902 trial as it seems much broader than what TH has said. Are the cancers they note on their websites just subsets of the cancers TH said the phase 1b will test?

scarlet1967 wrote: The professor in charge...

“Specialty

IM/Hematology/Oncology

Research Profile

The research of Monica Mita, MD, focuses on the phase I clinical trials in oncology, novel drugs and targeted therapies.

Education

Medical School: Carol Davila University, Romania, 1992

Fellowship: University of Texas Health Science Center, 2005

Fellowship: Cancer Therapy and Research Center, 2006”

https://bio.cedars-sinai.org/mitam/index.html